JAMA

Single-dose LSD therapy significantly reduces anxiety in GAD patients

September 15, 2025

A single administration of MM120 (lysergide D-tartrate) demonstrated dose-dependent efficacy in reducing anxiety symptoms in generalized anxiety disorder (GAD), with 100 µg identified as the optimal dose for future trials. The findings support further investigation of MM120 as a potential fast-acting, non-daily treatment option for GAD.

Study details: This phase 2b, multicenter, randomized, double-blind, placebo-controlled trial (NCT05407064) evaluated the dose-response efficacy of MM120 in 198 adults (mean age 41 years; 57% female) with moderate to severe GAD. Participants received a single dose of MM120 (25, 50, 100, or 200 µg) or placebo. Primary endpoint was change in Hamilton Anxiety Rating Scale (HAM-A) score at week 4.

Results: The 100 µg and 200 µg MM120 groups showed statistically significant reductions in HAM-A scores compared with placebo (least-squares mean difference: −5.0 and −6.0 points, respectively). Lower doses (25 and 50 µg) didn’t reach significance (least-squares mean difference, -1.2 points; 95% confidence interval [CI], -6.0 to 3.5 points and -1.8 points; 95% CI, -7.6 to 4.0 points, respectively). Adverse events were dose-related and included visual perceptual changes, nausea, and headache, with higher incidence at higher doses.

Source:

Robison R, et al. (2025, September 4). JAMA. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/40906494/